- Home
- HSPO vs ALVR Comparison
HSPO vs ALVR Comparison
Compare HSPO & ALVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSPO
- ALVR
- Stock Information
- Founded
- HSPO 2014
- ALVR 2013
- Country
- HSPO United States
- ALVR United States
- Employees
- HSPO N/A
- ALVR N/A
- Industry
- HSPO Blank Checks
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HSPO Finance
- ALVR Health Care
- Exchange
- HSPO Nasdaq
- ALVR Nasdaq
- Market Cap
- HSPO 87.7M
- ALVR 87.7M
- IPO Year
- HSPO 2022
- ALVR 2020
- Fundamental
- Price
- HSPO $11.25
- ALVR $0.90
- Analyst Decision
- HSPO
- ALVR Sell
- Analyst Count
- HSPO 0
- ALVR 5
- Target Price
- HSPO N/A
- ALVR $1.00
- AVG Volume (30 Days)
- HSPO 27.4K
- ALVR 155.6K
- Earning Date
- HSPO 01-01-0001
- ALVR 11-04-2024
- Dividend Yield
- HSPO N/A
- ALVR N/A
- EPS Growth
- HSPO N/A
- ALVR N/A
- EPS
- HSPO 0.33
- ALVR N/A
- Revenue
- HSPO N/A
- ALVR N/A
- Revenue This Year
- HSPO N/A
- ALVR N/A
- Revenue Next Year
- HSPO N/A
- ALVR N/A
- P/E Ratio
- HSPO $34.26
- ALVR N/A
- Revenue Growth
- HSPO N/A
- ALVR N/A
- 52 Week Low
- HSPO $10.60
- ALVR $0.58
- 52 Week High
- HSPO $11.25
- ALVR $2.49
- Technical
- Relative Strength Index (RSI)
- HSPO 69.42
- ALVR 69.10
- Support Level
- HSPO $11.17
- ALVR $0.74
- Resistance Level
- HSPO $11.25
- ALVR $0.91
- Average True Range (ATR)
- HSPO 0.00
- ALVR 0.06
- MACD
- HSPO 0.00
- ALVR 0.01
- Stochastic Oscillator
- HSPO 100.00
- ALVR 94.50
About HSPO Horizon Space Acquisition I Corp.
Horizon Space Acquisition I Corp is a blank check company.
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.